Belgian experience with direct acting antivirals in people who inject drugs

Drug and Alcohol Dependence

Volumn 177, Issue , 2017, Pages 214-220

  Bielen, Rob ^a   Moreno, Christophe ^b   Van Vlierberghe, Hans ^c   Bourgeois, Stefan ^d   Mulkay, Jean Pierre ^e   Vanwolleghem, Thomas ^f   Verlinden, Wim ^f   Brixko, Christian ^g   Decaestecker, Jochen ^h   De Galocsy, Chantal ⁱ   Janssens, Filip ^h   Cool, Mike ^h   Van Overbeke, Lode ^j   Van Steenkiste, Christophe ^c   D'heygere, François ^h   Cools, Wilfried ^a   Nevens, Frederik ^h   Robaeys, Geert ^h  

^a HASSELT UNIVERSITY   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d Stuivenberg General Hospital   (Belgium)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g CHR Citadelle ^*  (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HIS Bracops Department of Gastro enterology   (Belgium)

^j Algemeen Ziekenhuis Sint Maarten   (Belgium)

more..

Author keywords

Direct acting antiviral therapy; Hepatitis c virus; Intravenous drug use; People who inject drugs; Treatment uptake

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL; OMBITASVIR; PARITAPREVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISCELLANEOUS NAMED GROUPS; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUGS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; BELGIUM; DRUG EFFECTS; HEPACIVIRUS; SUBSTANCE ABUSE;

ADULT; AGED; ANTIVIRAL AGENTS; BELGIUM; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMEPREVIR; SOFOSBUVIR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85020640025     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.04.003     Document Type: Article

References (43)

1. Arain, A., Robaeys, G., Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J. Gastroenterol. 20 (2014), 12722–12733.
2. Arain, A., Bourgeois, S., de Galocsy, C., Henrion, J., Deltenre, P., d'Heygere, F., George, C., Bastens, B., Van Overbeke, L., Verrando, R., Bruckers, L., Mathei, C., Buntinx, F., Van Vlierberghe, H., Francque, S., Laleman, W., Moreno, C., Janssens, F., Nevens, F., Robaeys, G., Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. J. Med. Virol. 88 (2015), 94–99.
3. Asher, A.K., Portillo, C.J., Cooper, B.A., Dawson-Rose, C., Vlahov, D., Page, K.A., Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst. Use Misuse 51 (2016), 1218–1223.
4. Aspinall, E.J., Corson, S., Doyle, J.S., Grebely, J., Hutchinson, S.J., Dore, G.J., Goldberg, D.J., Hellard, M.E., Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin. Infect. Dis. 57:Suppl. 2 (2013), S80–89.
5. Belgian Association for Study of the Liver, In Hepatitis C: Cut-off's Elastography and Biological Testing for METAVIR F3-F4 and Treatment Options in BELGIUM: Update 06/12/2015. 2015 http://www.basl.be/treatmentoptionsanddiagnosticcutoffshcvbelgium.
6. Dalgard, O., Bjøro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., Bell, H., Group, C., Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur. Addict. Res. 8 (2002), 45–49.
7. Dimova, R.B., Zeremski, M., Jacobson, I.M., Hagan, H., Des Jarlais, D.C., Talal, A.H., Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin. Infect. Dis. 56 (2013), 806–816.
8. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.Y., Conway, B., Grebely, J., Howe, A.Y., Gendrano, I.N., Chen, E., Huang, H.C., Dutko, F.J., Nickle, D.C., Nguyen, B.Y., Wahl, J., Barr, E., Robertson, M.N., Platt, H.L., Group, C.E.C.-S.S., Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann. Intern. Med. 165 (2016), 625–634.
9. Evon, D.M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C., Fried, M.W., A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am. J. Gastroenterol. 106 (2011), 1777–1786.
10. Feld, J.J., Kowdley, K.V., Coakley, E., Sigal, S., Nelson, D.R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., DaSilva-Tillmann, B., Larsen, L., Podsadecki, T., Bernstein, B., Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370 (2014), 1594–1603.
11. Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R.T., Tsai, N., Nyberg, A., Box, T.D., Younes, Z., Enayati, P., Green, S., Baruch, Y., Bhandari, B.R., Caruntu, F.A., Sepe, T., Chulanov, V., Janczewska, E., Rizzardini, G., Gervain, J., Planas, R., Moreno, C., Hassanein, T., Xie, W., King, M., Podsadecki, T., Reddy, K.R., Study, P.-I., Study, P.-I., ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370 (2014), 1983–1992.
12. Garimella, T., Wang, R., Luo, W.L., Wastall, P., Kandoussi, H., DeMicco, M., Bruce, R.D., Hwang, C., Bertz, R., Bifano, M., Assessment of drug–drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob. Agents Chemother. 59 (2015), 5503–5510.
13. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61 (2014), S45–57.
14. Grady, B.P., Schinkel, J., Thomas, X.V., Dalgard, O., Hepatitis C virus reinfection following treatment among people who use drugs. Clin. Infect. Dis. 57:Suppl. 2 (2013), S105–110.
15. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Byrne, J., Dalgard, O., Feld, J.J., Hellard, M., Hickman, M., Kautz, A., Litwin, A., Lloyd, A.R., Mauss, S., Prins, M., Swan, T., Schaefer, M., Taylor, L.E., Dore, G.J., International Network for Hepatitis in Substance, U., Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int. J. Drug Policy 26 (2015), 1028–1038.
16. Grebely, J., Alavi, M., Micallef, M., Dunlop, A.J., Balcomb, A.C., Phung, N., Weltman, M.D., Day, C.A., Treloar, C., Bath, N., Haber, P.S., Dore, G.J., Group, E.S., Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction 111 (2016), 311–319.
17. Grebely, J., Dore, G.J., Zeuzem, S., Aspinall, R.J., Fox, R., Han, L., McNally, J., Osinusi, A., Brainard, D.M., Subramanian, G.M., Natha, M., Foster, G.R., Mangia, A., Sulkowski, M., Feld, J.J., Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin. Infect. Dis. 63 (2016), 1479–1481.
18. Hickman, M., De Angelis, D., Vickerman, P., Hutchinson, S., Martin, N.K., Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr. Opin. Infect. Dis. 28 (2015), 576–582.
19. Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Scott, J., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
20. Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., Shiffman, M.L., Schiff, E., Ghalib, R., Ryan, M., Rustgi, V., Chojkier, M., Herring, R., Di Bisceglie, A.M., Pockros, P.J., Subramanian, G.M., An, D., Svarovskaia, E., Hyland, R.H., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Pound, D., Fried, M.W., Investigators, I.O.N., Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370 (2014), 1879–1888.
21. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., Aguilar, H., Felizarta, F., McGovern, B., King, M., Polepally, A.R., Cohen, D.E., Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J. Hepatol. 63 (2015), 364–369.
22. Lawitz, E., Sulkowski, M.S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z.M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., Lim, J.K., Pockros, P.J., Scott, J.D., Fevery, B., Lambrecht, T., Ouwerkerk-Mahadevan, S., Callewaert, K., Symonds, W.T., Picchio, G., Lindsay, K.L., Beumont, M., Jacobson, I.M., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
23. Manns, M., Marcellin, P., Poordad, F., de Araujo, E.S., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384 (2014), 414–426.
24. Marinho, R.T., Barreira, D.P., Hepatitis C, stigma and cure. World J. Gastroenterol. 19 (2013), 6703–6709.
25. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54 (2011), 1137–1144.
26. Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55 (2012), 49–57.
27. Matheï, C., Robaeys, G., van Damme, P., Buntinx, F., Verrando, R., Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol. Infect. 133 (2005), 127–136.
28. Matheï, C., Bourgeois, S., Blach, S., Brixko, C., Mulkay, J.P., Razavi, H., Robaeys, G., Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg 79:2 (2016 Apr-Jun), 227–232.
29. Midgard, H., Bjoro, B., Maeland, A., Konopski, Z., Kileng, H., Damas, J.K., Paulsen, J., Heggelund, L., Sandvei, P.K., Ringstad, J.O., Karlsen, L.N., Stene-Johansen, K., Pettersson, J.H., Dorenberg, D.H., Dalgard, O., Hepatitis C reinfection after sustained virological response. J. Hepatol. 64 (2016), 1020–1026.
30. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., Degenhardt, L., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
31. Ogbuagu, O., Friedland, G., Bruce, R.D., Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin. Drug Metab. Toxicol. 12 (2016), 721–731.
32. Pawlotsky, J.M., A.A, Back, D., Dusheiko, G., Forms, X., Puonti, M., Sarrazin, C., European association for study of liver: EASL recommendations on treatment of hepatitis C. J. Hepatol. 63 (2015), 199–236.
33. Pol, S., Corouge, M., Vallet-Pichard, A., Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat. Med. 8 (2016), 21–26.
34. Robaeys, G., Buntinx, F., Treatment of hepatitis C viral infections in substance abusers. Acta. Gastroenterol. Belg. 68 (2005), 55–67.
35. Robaeys, G., Van Vlierberghe, H., Matheï, C., Van Ranst, M., Bruckers, L., Buntinx, F., B.S. Committee, B.S. Group, Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol. 18 (2006), 159–166.
36. Robaeys, G., Bielen, R., Azar, D.G., Razavi, H., Nevens, F., Global genotype distribution of hepatitis C viral infection among people who inject drugs. J. Hepatol. 65 (2016), 1094–1103.
37. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A.S., Hinestrosa, F., Thuluvath, P.J., Schwartz, H., Nelson, D.R., Everson, G.T., Eley, T., Wind-Rotolo, M., Huang, S.P., Gao, M., Hernandez, D., McPhee, F., Sherman, D., Hindes, R., Symonds, W., Pasquinelli, C., Grasela, D.M., Group, A.S., Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370 (2014), 211–221.
38. Sylvestre, D.L., Clements, B.J., Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur. J. Gastroenterol. Hepatol. 19 (2007), 741–747.
39. Valerio, H., Goldberg, D.J., Lewsey, J., Weir, A., Allen, S., Aspinall, E.J., Barclay, S.T., Bramley, P., Dillon, J.F., Fox, R., Fraser, A., Hayes, P.C., Innes, H., Kennedy, N., Mills, P.R., Stanley, A.J., Hutchinson, S.J., Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: implications for reinfection. Drug Alcohol Depend. 154 (2015), 125–131.
40. WHO, World Health Organization: Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection. 2016.
41. WHO, Global Burden of Disease and WHO/UNAIDS Estimates. 2016 see http://ihmeuw.org/3pms, http://ihmeuw.org/3pmt (Accessed 2 April, 2016).
42. Willemse, S.B., Baak, L.C., Kuiken, S.D., van der Sluys Veer, A., Lettinga, K.D., van der Meer, J.T., Depla, A.C., Tuynman, H., van Nieuwkerk, C.M., Schinkel, C.J., Kwa, D., Reesink, H.W., van der Valk, M., Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J. Viral Hepat. 23 (2016), 950–954.
43. Zeuzem, S., Jacobson, I.M., Baykal, T., Marinho, R.T., Poordad, F., Bourliere, M., Sulkowski, M.S., Wedemeyer, H., Tam, E., Desmond, P., Jensen, D.M., Di Bisceglie, A.M., Varunok, P., Hassanein, T., Xiong, J., Pilot-Matias, T., DaSilva-Tillmann, B., Larsen, L., Podsadecki, T., Bernstein, B., Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370 (2014), 1604–1614.